Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Cash from Operations for 10 consecutive years, with $47.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 68.01% year-over-year to $47.2 million; the trailing twelve-month figure through Jun 2026 stood at $185.0 million (up 176.28% YoY), and the FY2025 full-year result was $138.0 million, up 437.14% from the prior year.
• Cash from Operations slipped to $47.2 million in Q2 2026 per KNSA's latest filing, from $50.2 million in the prior quarter.
• Across five years, Cash from Operations topped out at $62.1 million in Q3 2022 and bottomed at -$36.8 million in Q1 2022.
• Historically, Cash from Operations has averaged $15.6 million across 5 years, with a median of $11.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 113.16% in 2024, then surged 1606.13% in 2025.
• Over 5 years, Cash from Operations stood at -$11.6 million in 2022, then jumped by 137.36% to $4.3 million in 2023, then surged by 333.99% to $18.8 million in 2024, then jumped by 187.13% to $53.9 million in 2025, then fell by 12.43% to $47.2 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $47.2 million, $50.2 million, and $53.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.